Infinity Pharma (INFI) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Infinity Reports First Quarter 2015 Financial Results and Recent Corporate Developments
May 6, 2015 8:02 AM EDT- Patient Enrollment in DYNAMOTM Now Expected to Be Completed in Second Half 2015
- DUOTM Enrollment On-Track for Completion in Second Half 2015
- Further Expansion of Duvelisib Development Program Expected in 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2015 financial results and ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity also provided updated guidance on the enrollment timing for DYNAMO, a Phase... More
